Millstone Evans Group’s VanEck Biotech ETF BBH Stock Holding History

Millstone Evans Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.96K	Hold	37	–	–	﹤0.01%	615
2025 Q4	$7K	Hold	37	–	–	﹤0.01%	604
2025 Q3	$6.13K	Buy	+37	New	+$6.03K	﹤0.01%	603

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

Millstone Evans Group's BBH Position: Q1 2026 in Review

Millstone Evans Group held its VanEck Biotech ETF (BBH) position steady in Q1 2026 at 37 shares worth $6.96K. The position accounts for ﹤0.01% of the portfolio, ranked #615.

Millstone Evans Group first reported a position in BBH in Q3 2025 and has held it in 3 quarters since. The position peaked at $7K in Q4 2025. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

Millstone Evans Group held 37 shares of VanEck Biotech ETF worth $6.96K as of Q1 2026.
Millstone Evans Group left its VanEck Biotech ETF share count unchanged in Q1 2026.
VanEck Biotech ETF made up ﹤0.01% of Millstone Evans Group's portfolio in Q1 2026, its #615 holding.
Millstone Evans Group first reported a position in VanEck Biotech ETF in Q3 2025 and has held it in 3 quarters since.
Millstone Evans Group's VanEck Biotech ETF position peaked at $7K in Q4 2025.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Millstone Evans Group's 13F filing for Q1 2026, filed 30 Apr 2026.